Anti-coagulant treatment Haematological Disorders Other coagulation defects
Conditions
Interventions
The participants will be randomly allocated to the following four groups in equal numbers:
Group 1: 100 µg vitamin K1 (oral), 1 capsule per day (1 dd)
Group 2: 150 µg v
Sponsors
Netherlands Heart Foundation (Nederlandse Hartstichting) (The Netherlands)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Start treatment with vitamin K antagonists less then four weeks before inclusion 2. Treatment with vitamin K antagonists for a minimal period of six months, with the therapeutic range of International normalised ratio (INR) between 2.5 anf 3.5 3. Aged between 18 and 85 years, either sex 4. Measurement of the INR by the Thrombosis Service Leiden 5. Informed consent
Exclusion criteria
Exclusion criteria: 1. Treatment for liver failure 2. Dialysis, both peritoneal and haemodialysys 3. Pregnancy, or wish to get pregnant; lactational period 4. Known to have a chronic condition with a life expectancy of less than six months 5. An expected interruption of treatment with oral anti-coagulants for one week or longer 6. Participation in the self-management protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of anti-coagulant treatment expressed as time in therapeutic range. Duration of follow-up: until six months after the closure of the inclusion period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of INRs in therapeutic range. Duration of follow-up: until six months after the closure of the inclusion period. | — |
Countries
Netherlands
Outcome results
None listed